April 8, 2026
Digital solution will be designed to help guide users through injection process.
Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (āEnableā), a healthcare innovation company developing and manufacturing the enFuseĀ® On-Body Delivery System, today announced a strategic partnership naming Aptar Digital Health as Enableās preferred digital health partner for the enFuseĀ® system. This digital solution will be designed to guide patients and caregivers throughout the injection process and help support engagement before, during, and after administration.
Through this partnership, Aptar Digital Health will deliver a companion digital solution for Enable Injectionsā enFuseĀ® system designed to enhance the patient experience and support adherence-related programs. Key features of the solution may include treatment data recording, onboarding and training modules, injection guidance, patient-reported outcomes and symptom tracking – helping to empower patients and caregivers with greater confidence and control over the treatment process.
Built on a flexible and scalable architecture, the companion digital solution will be deployed alongside the enFuseĀ® system, enabling pharmaceutical partners to extend the value of their therapies beyond delivery. Designed to evolve across the drug development lifecycle, the digital solution may support use cases from clinical trials through commercialization, aligned with development and launch strategies.
Adherence data and patient reported outcomes will be captured remotely, securely stored and made available through analytics dashboards that generate actionable insights intended to support clinical development, launch readiness and real-world use. The modular, program-specific design will allow pharmaceutical partners to integrate digital components into their clinical or commercial programs based on their needs. By combining device-generated data with patient reported insights, the digital solution will help drive more informed decisions grounded in real-world usage.
āThis collaboration seeks to enhance the treatment experience of patients beyond the moment of injection,ā said Michael D. Hooven, Chairman and CEO of Enable Injections. āTogether, we will combine innovative drug delivery with digital support tools. This can help patients remain engaged in their therapy and enable healthcare providers to better understand and support each patientās journey.ā
āWe are excited to partner with Enable Injections to help bring the next generation of drug delivery solutions to life,ā said Damien McKeon, SVP Strategic Partnerships, Aptar Digital Health. āLarge-volume biologic therapies are increasingly used to treat complex chronic conditions. They often require long-term adherence to achieve optimal outcomes. Digital solutions supporting treatment tracking and patient engagement can help address common adherence challenges associated with self-administration.ā
About Aptar Digital Health
Aptar Pharma’s Digital Health division is part of AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, including dosing and protection technologies, and consumer product dispensing. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Healthās offering combines mobile and web apps, Software-as-Medical-Device, connected drug delivery systems, advanced data analysis services, and patient onboarding and training solutions to actively empower patients and create a positive treatment journey. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries.
About Enable Injections
Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuseĀ® on-body drug delivery system. An innovative wearable technology, the enFuseĀ® system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting improved outcomes, and advancing healthcare system economics.
Enable is currently working with a number of pharmaceutical partners to conduct clinical trials and plan for the joint commercial launch of their therapies in combination with the enFuseĀ® technology. For more information, visit www.enableinjections.com.
18 – 22 April 2026
Chicago
Meet with the Aptar Digital Health team at the Annual Meeting of the American Academy of Neurology to discuss our capabilities and portfolio of digital health solutions in neurology, including Migraine Buddy, used by millions of migraine sufferers worldwide. Don’t miss our latest abstract, co-authored by our Head of Clinical Product Development, Alexandre Urani. Fill our the form to book a meeting!
22 – 24 April 2026
Barcelona
Meet with Aptar Digital Health team at Reuters Pharma EU in Barcelona. Our Business Development team will be on-site to discuss how digital health can enhance the patient experience, improve medication adherence and clinical outcomes. Aptar Digital Health is excited to chair the “Digital Patient Engagement” track for the three days of the conference. Book your meeting now to engage with our team.
15 – 18 June 2026
Amsterdam
Meet with Aptar Digital Health during HLTH Europe, in Amsterdam this June! The team will be on-site to meet in person and discuss strategic alliances to enhance your patients’ experience. Join our CBO on the Life Science stage on June 16th to learn more on how digital apps turn real-world patient experiences into continuous, actionable insights, helping generating evidence, guiding strategy, and moving toward more patient-centered, data-driven decisions. Fill out the form to book your meeting.
